Abstract
Solitary fibrous tumor (SFT) can occur at any age (Fig. 11.1) and any site (Fig. 11.2). As with vascular sarcomas, solitary fibrous tumor/hemangiopericytoma (SFT/HPC) represents a spectrum of tumors ranging from well-circumscribed tumors with bland spindle-shaped cells to histologically malignant tumors with a high mitotic rate and significant risk of metastatic disease. SFT/HPC arises in the pleura, pelvis, and in the dura, where it is termed hemangiopericytoma exclusively by neuropathologists. Even among neuropathologists, there is increasing appreciation that what has been termed HPC and SFT are indeed related [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Miettinen M. Antibody specific to muscle actins in the diagnosis and classification of soft tissue tumors. Am J Pathol. 1988;130(1):205–15.
Porter PL, Bigler SA, McNutt M, et al. The immunophenotype of hemangiopericytomas and glomus tumors, with special reference to muscle protein expression: an immunohistochemical study and review of the literature. Mod Pathol. 1991;4(1):46–52.
Hajdu M, Singer S, Maki RG, et al. IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. J Pathol. 2010;221(3):300–7.
Espat NJ, Lewis JJ, Leung D, et al. Conventional hemangiopericytoma: modern analysis of outcome. Cancer. 2002;95(8):1746–51.
Domont J, Massard C, Lassau N, et al. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangiopericytoma/solitary fibrous tumour. Invest New Drugs. 2010;28(2):199–202.
Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011;117(21):4939–47.
Gold JS, Antonescu CR, Hajdu C, et al. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002;94(4):1057–68.
Stacchiotti S, Negri T, Palassini E, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010;9(5):1286–97.
George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27(19):3154–60.
Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753–9.
Chamberlain MH, Taggart DP. Solitary fibrous tumor associated with hypoglycemia: an example of the Doege-Potter syndrome. J Thorac Cardiovasc Surg. 2000;119(1):185–7.
Roy TM, Burns MV, Overly DJ, et al. Solitary fibrous tumor of the pleura with hypoglycemia: the Doege-Potter syndrome. J Ky Med Assoc. 1992;90(11):557–60.
Baldwin RS. Hypoglycemia with Neoplasia (Doege-Potter syndrome). Wis Med J. 1965;64:185–9.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Brennan, M.F., Antonescu, C.R., Maki, R.G. (2013). Solitary Fibrous Tumor/Hemangiopericytoma. In: Management of Soft Tissue Sarcoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5004-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5004-7_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5003-0
Online ISBN: 978-1-4614-5004-7
eBook Packages: MedicineMedicine (R0)